Poster presentations: Treatment 2021
12 posters
Slowly expanding lesions as an imaging marker in MS: the effect of evobrutinib
Douglas L. Arnold
45
Brain Volume Changes During 3 to 5 Years of Ozanimod in Relapsing MS
Douglas L. Arnold
56
Characterisation of the immune system after ocrelizumab treatment in MS
Young Investigator
Lien Beckers
53
Systemic corticosteroid therapy and visual outcome of ischemic optic neuropathy
Young Investigator
Sofia Bezerra de Oliveira Costa
46
NfL levels in patients with MS: prognostic value and effect of evobrutinib
Jens Kuhle
44
TDCS to prevent optic nerve damage and to promote remyelination in EAE mouse model
Winner Young Investigator Award
Young Investigator
Silvia Marenna
39
Satisfaction and practicality of branded glatiramer acetate pen in RRMS patients
Herbert Schreiber
18
PROFILE RMS interim analysis: Unmet medical needs in the care of relapsing MS
Herbert Schreiber
37
Long-term Safety and Efficacy of Ozanimod in RMS: Interim Analysis of DAYBREAK
Krzysztof Selmaj
57
Ph3 results of the ULTIMATEI&II global studies: Ublituximab v. teriflunomide in RMS
Lawrence Steinman
47